Equity-Accounted Investees and Joint Business (Tables)

12 Months Ended

Dec. 31, 2025

Equity-Accounted Investees and Joint Business

Schedule of details of equity accounted investees and joint business


				Millions of Euros				Millions of Euros
		*% ownership ()**		31/12/2025		*% ownership ()**		31/12/2024
Grifols Egypt for Plasma Derivatives S.A.E.		49.00	%	76		49.00	%	63
BioDarou P.J.S. Co.		39.40	%	2		34.30	%	6
Grifols Canada Plasma, Inc.		50.10	%	19		—	%	—

Total equity - accounted investees				97				69

(*) This percentage also refers to the voting interest.

Schedule of movement in investments in equity-accounted investees


		Millions of Euros
		2025
		Equity accounted investees with similar activity to that of the Group
		Grifols Egypt for
		Plasma Derivatives				Grifols Canada
		S.A.E.		BioDarou P.J.S. Co.		Plasma, Inc.		Total
Balance at 1 January		63		6		—		69

Acquisitions		20		—		19		39
Share of profit / (losses)		(4)		—		—		(4)
Share of other comprehensive income / translation differences		(3)		—		—		(3)
Collected dividends		—		—		—		—
Impairment loss		—		(4)		—		(4)
Transfers		—		—		—		—
Balance at 31 December		76		2		19		97


		Millions of Euros
		2024
		Equity accounted investees with similar activity to that of the Group								Rest of equity accounted investees
		Shanghai RAAS		Grifols Egypt
		Blood Products		for Plasma		BioDarou
		Co., Ltd.		Derivatives S.A.E.		P.J.S. Co.		Total		Mecwins, S.A.		Total		Total
Balance at 1 January		361		46		11		418		3		3		421

Acquisitions		—		41		—		41		—		—		41
Share of profit / (losses)		13		—		(4)		9		—		—		9
Share of other comprehensive income / translation differences		—		(24)		5		(19)		—		—		(19)
Collected dividends		(7)		—		—		(7)		—		—		(7)
Uncollected dividends		—		—		(6)		(6)		—		—		(6)
Transfers		(367)		—		—		(367)		(3)		(3)		(370)
Balance at 31 December		—		63		6		69		—		—		69


		Millions of Euros
		2023
		Equity accounted investees with similar activity to that of the Group								Rest of equity accounted investees
		Shanghai RAAS		Grifols Egypt						Albajuna
		Blood Products		for Plasma		BioDarou				Therapeutics,		Mecwins,
		Co., Ltd.		Derivatives S.A.E.		P.J.S. Co.		Total		S.L		S.A.		Total		Total
Balance at 1 January		1,453		36		5		1,494		1		3		4		1,498
Acquisitions		—		20		—		20		—		—		—		20
Share of profit / (losses)		62		(1)		3		64		(1)		—		(1)		63
Share of other comprehensive income / translation differences		(57)		(9)		4		(62)		—		—		—		(62)
Collected dividends		(7)		—		—		(7)		—		—		—		(7)
Uncollected dividends		—		—		(1)		(1)		—		—		—		(1)
Transfers		(1,090)		—		—		(1,090)		—		—		—		(1,090)
Balance at 31 December		361		46		11		418		—		3		3		421

Schedule of sale of ownership interests


		Million of euros
Selling price		1,608
Fair value of SRAAS 6.58%		434
Minus: book value of the Non-current asset held for sale and transaction costs		(1,124)
Minus: book value of the Investment accounted for using the equity method as the date of loss of the significant influence		(368)
Minus:increase of the minority interest of GDS (see Note 19)		(508)
Other contractual obligations (see Note 29)		(10)
Result before the reclassification of translation differences		32
Accumulated translation differences in equity		2
Transaction result: profit		34
Taxes on profits in China and Spain		(35)
Result net of taxes		(1)

Schedule of last financial statements available for the main equity-accounted investments of Grifols


		Millions of Euros
		31/12/2025				31/12/2024
		Grifols Egypt for				Grifols Egypt for
		Plasma Derivatives		Grifols Canada		Plasma Derivatives
		S.A.E.		Plasma, Inc.		S.A.E.
Non-current assets		115		13		98
Current assets		101		8		92
Cash and cash equivalents		22		2		29
Non-current liabilities		(9)		(7)		(7)
Non-current financial liabilities		(8)		(7)		(7)
Current liabilities		(46)		(18)		(45)
Net assets		175		(9)		160

P&L:


		Millions of Euros
		2025				2024		2023
		Grifols Egypt for				Grifols Egypt for		Shanghai RAAS		Grifols Egypt for
		Plasma Derivatives		Grifols Canada		Plasma Derivatives		Blood Products Co.,		Plasma Derivatives
		S.A.E.		Plasma, Inc.		S.A.E.		Ltd.		S.A.E.
Net revenue		28		3		13		778		—
Net profit		(13)		—		4		234		(4)

Schedule of net of deposits


		Millions
		US Dollar		Euros
Group 3		78		75
Group 4		62		59
Total		140		134

Biotek America LLC

Equity-Accounted Investees and Joint Business

Schedule of consolidated financial statements


		Millions
		US Dollars		Euros
		31/12/2024		31/12/2024
Non-current assets		54		52
Current assets		27		26
Total assets		81		78

Non-current liabilities		56		54
Current liabilities		47		45
Total liabilities		103		99

Grifols’ balances		6		6
Total Equity		(28)		(27)


		Millions
		US Dollars		Euros
		31/12/2024		31/12/2024
Net revenue		206		190
Net profit		6		6